Neck management in patients with olfactory neuroblastoma

Song, Xinmao; Huang, Chuang; Wang, Shengzi; Li, Yan; Wang, Jie; Li, Yang

doi:10.1016/j.oraloncology.2019.104505

Cited by 17 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most cervical lymph node metastasis occurred in level II, followed by levels I, III and retropharyngeal lymph nodes (7,55,56). The observations of Song et al (54) differed somewhat from those of previous reports, as they observed that Ib and VIIa were most frequently affected after level II. In our study, lymph node metastasis most commonly occurred in level II and III.…”

Section: Discussionmentioning

confidence: 67%

“…The basic clinical information is presented in Table 3. Local failure has been reported in nearly 10-30% of cases, while regional failure have been reported in nearly 10-20% and distant metastasis have been reported in nearly 5-10% (3,8,9,17,20,21,54). This suggests that patients are at relatively high risk for recurrence.…”

Section: Discussionmentioning

confidence: 99%

“…There is considerable controversy about whether patients with negative cervical lymph nodes should receive prophylactic neck radiation therapy. One study reported that elective nodal irradiation (ENI) can reduce the rate of cervical nodal failure from 10.7 to 1.6% for N0 disease, but did not improve final survival outcomes (54). Noh et al hold a conservative attitude to the prophylactic radiation of cervical lymph nodes, and they think that the ENI can be omitted for N0 disease when patients are undergoing radiotherapy and chemotherapy (57).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma

Zeng

Tian

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Background: Esthesioneuroblastoma (ENB) is a rare sinonasal malignancy, lacking a unified staging system and treatment. Management at a single center was retrospectively evaluated to inform future treatment options and prognostic factors.Methods: Clinical data of 64 consecutive ENB patients, including prognostic factors and treatment methods, were reviewed retrospectively. Data were collected to calculate overall survival (OS) and progression free survival (PFS).Results: The majority of tumors 84.4% were within Kadish C stage, 79.7% were within T3 or T4, and 64.0% were within Hyams grade III or IV. A total of 50 (78.1%) patients received surgery and combined radiotherapy with or without chemotherapy, 10 (15.6%) received surgery with or without chemotherapy alone, and 4 (6.3%) received radiotherapy with or without chemotherapy alone. The majority of patients (79.7%) underwent endoscopic resection (endoscopic and endoscopically assisted). Surgery combined with radiotherapy with or without chemotherapy resulted in significantly better OS (84.4 vs. 50.6%, 84.4 vs. 37.5%) compared to surgery alone and radiotherapy alone (P = 0.0064). Endoscopic surgery group (endoscopic and endoscopically assisted) resulted in significantly better 5-year PFS (61.7 vs. 22.2%) compared to the open surgery group (P < 0.001). Although endoscopic surgery group was not a statistically significant predictor of 5-year OS (P = 0.54), the 5-year OS was 79.3% for the endoscopic surgery group and 76.2% for the open surgery group. A Cox regression analysis identified intracranial extension and surgery combined with radiotherapy as independent factors affecting 5-year OS while cervical lymph node metastasis and Hyams grade IV as independent factors affecting 5-year PFS.Conclusion: Our findings suggest that surgery combined with radiotherapy is the best treatment approach for ENB. For advanced tumors, endoscopic surgery is an effective treatment, and its survival rate is equal to or better than open surgery.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma

Zeng

Tian

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…After title and abstract review, 350 articles were rejected and full-texts of the remaining 66 papers were obtained for further review. After applying the aforementioned eligibility criteria, a total of 9 studies were included in the qualitative and quantitative synthesis (22)(23)(24)(25)(26)(27)(28)(29)(30) . The reasons behind the exclusions of the other studies are shown in Figure 1.…”

Section: Literature Search Resultsmentioning

confidence: 99%

Elective neck irradiation in the management of esthesioneuroblastoma: a systematic review and meta-analysis

Costantino¹,

Sebastiani²,

Russo³

et al. 2021

Rhin

View full text Add to dashboard Cite

Background: There is no consensus about the optimal management of the neck in clinically node negative esthesioneuroblastoma (ENB). The aim of this study is to assess the impact of elective neck irradiation (ENI) in terms of regional disease control and survival. Methods: The study was performed according to the PRISMA guidelines searching on Scopus, PubMed/MEDLINE, and Google Scholar databases. The primary outcome was the regional recurrence rate (RRR), that was reported as odds ratio (OR) and 95% confidence interval (CI). Secondary outcomes were the overall survival (OS), and the distant-metastases free survival (DMFS), that were reported as logarithm of the hazard ratios (logHRs) and 95% confidence intervals (CIs). Results: A total of 489 clinically node negative patients were included from 9 retrospective studies. ENI significantly reduced the risk of regional recurrence compared to no treatment. No difference was measured between ENI and observation, according to both OS and DMFS. No stratified analysis could be performed based on Kadish stage and Hyams grade. Conclusions: ENI should be recommended to improve the regional disease control. No advantage was measured in terms of survival or distant metastases with a low quality of evidence. Further prospective studies should be designed to understand if ENI could be avoided in early stage and low-grade tumors.

show abstract

“…It is an embryonic tumour arising from precursor cells in the sympathetic nervous system and adrenal medulla 2 , with a median age of diagnosis of 18 months 3 . It can also present in the neck, chest, abdomen or pelvis 4 . Neuroblastoma is a highly heterogeneous disease, with clinical behavior ranging from spontaneous regression to drug resistance and metastasis ultimately resulting in death 5 .…”

Section: Introductionmentioning

confidence: 99%

Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification

Zhou

Hill

et al. 2021

Preprint

View full text Add to dashboard Cite

Despite the extensive study of MYCN-amplified neuroblastomas, there is a significant unmet clinical need in MYCN non-amplified neuroblastomas. In particular, the extent of heterogeneity within the MYCN non-amplified population is unknown. Here, we investigate whether transcriptional subtyping of MYCN non-amplified neuroblastomas can identify molecular subtypes with discrete prognosis and therapeutic vulnerabilities. Using tumour expression data and ConsensusClusterPlus, we demonstrate that MYCN non-amplified neuroblastomas are heterogeneous and can be classified into 3 subgroups based on their transcriptional signatures. Within these groups, subgroup 2 has the worst prognosis and this group shows a "MYCN" signature that is potentially induced by the overexpression of Aurora Kinase A (AURKA); whilst subgroup 3 is characterised by an "inflamed" gene signature. The clinical implications of this subtype classification are significant, as each subtype demonstrates unique prognosis and vulnerability to investigational therapies. We propose that matching baseline tumour subtype to therapy may enhance precision prognosis and therapy stratification for patients with MYCN non-amplified neuroblastomas.

show abstract

Neck management in patients with olfactory neuroblastoma

Cited by 17 publications

References 21 publications

Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma

Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma

Elective neck irradiation in the management of esthesioneuroblastoma: a systematic review and meta-analysis

Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification

Contact Info

Product

Resources

About